-
Oragenics : Schedule filed to report acquisition of beneficial ownership of 5% or more of ...
#Oragenics#Stock#MarketScreener http://marketscreener.com/ORAGENICS-INC-40561583/news/Oragenics-Schedule-filed-to-report-acquisition-of-beneficial-ownership-of-5-or-more-of-a-class-of-29887724/ …pic.twitter.com/Wr4N7whUKZ
-
Oragenics : Current report filing Related Documents EX-99.1 EX-99.2
#Oragenics#Stock#MarketScreener http://marketscreener.com/ORAGENICS-INC-40561583/news/Oragenics-Current-report-filing-Related-Documents-EX-99-1-EX-99-2-29680439/ …pic.twitter.com/f6q332H0O4
-
#Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019$OGEN http://www.1stoncology.com/blog/oragenics-inc-to-present-at-the-ld-micro-12th-annual-main-event-on-december-10-20191234551884 … -
#Oragenics achieves chemical#synthesis of bicyclic C/D ring of lead#lantibiotic#Mutacin 1140 Step toward semisynthetic library of compounds vs#antibiotic-resistant#infections https://doi.org/10.1002/psc.3214 …#infectiousdisease@Wiley_Chemistry@CoreIR1pic.twitter.com/Rl7vS9dRmr
-
#Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications$OGEN http://www.1stoncology.com/blog/oragenics-inc-svp-of-discovery-research-martin-handfield-ph-d-to-be-featured-speaker-at-the-international-conference-on-microbial-researchapplications1234550876 … -
#Oragenics, Inc. Announces Phase 2 Clinical Trial of#AG013 Reaches Enrollment of 158 Patients$OGEN http://www.1stoncology.com/blog/oragenics-inc-announces-phase-2-clinical-trial-of-ag013-reaches-enrollment-of-158-patients1234539778 … -
$OGEN to Present a Corporate Overview and be available for one-on-one meetings at Upcoming Investment Conference#Oragenics http://crweworld.com/symbol/OGEN -
Oragenics : Quarterly report pursuant to Section 13 or 15(d) Related Documents EX-31.1 EX-...
#Oragenics#Stock#MarketScreener http://marketscreener.com/ORAGENICS-INC-40561583/news/Oragenics-Quarterly-report-pursuant-to-Section-13-or-15-d-Related-Documents-EX-31-1-EX-31-2-EX-32-29067829/ …pic.twitter.com/PEIFqKXric
-
$OGEN announces it will be presenting at the American Peptide Symposium on their novel peptide synthesis platform for its lantibiotic pipeline. Stock gains +10.42%#Oragenics https://www.newsquantified.com/ogen/stock-report/oragenics-inc-present-data-on-its-peptide-06kf6d#app0 … -
#Oragenics to present#lantibiotics#peptide#synthesis platform at#APS2019 Highlight#antimicrobial activity vs#Staph aureus#infection & synthesis of array of#Mutacin 1140 analogues https://www.oragenics.com/technology-pipeline/lantibiotics …#infectiousdisease#antibiotics @Peptides2019pic.twitter.com/VEc8ntxWSY
-
#Oragenics publishes#tolerability study of#lantibiotic lead OG253 in healthy rats Multiple doses well tolerated, no significant toxicity & remained compartmentalized to GI tract https://doi.org/10.1016/j.taap.2019.04.019 …#antibiotic#infectiousdisease$OGEN@Intrexonpic.twitter.com/nFSd31Cjsh
-
#Oragenics &@FIUMedicine collab on#computational#models & rational design of#lantobiotics Seek improved#antimicrobial & pharmacological properties for interactions w/ bacterial membranes https://www.oragenics.com/technology-pipeline/lantibiotics …#microbiology#infectiousdisease#Cdiff#antibiotics pic.twitter.com/eBKuMKlslL
-
#Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of#AG013 for#OralMucositis$OGEN http://www.1stoncology.com/blog/oragenics-inc-receives-clearance-to-enroll-patients-in-germanythe-united-kingdom-into-its-phase-2-clinical-trial-of-ag013-for-oral-mucositis … -
$OGEN stock rises +0.56% after Co. Announces 3Q 2018 Financial Results & Provides Corporate Update,#Oragenics https://hubs.ly/H0fxMQx0 -
#ALERT$OGEN is upping +50% now! The price is at 1,23$ after break the 1,20$ key. Keep watching the evolution of the price of#Oragenics in@MarcoDaCostaFX.#PENNYSTOCKSpic.twitter.com/yQ0azh6r9U
-
$OGEN stock rockets +34.23% after getting an OK to enroll patients in Belgium to its Phase 2 Trial#Oragenics https://hubs.ly/H0f8ZCp0 -
#Oragenics, Inc. (NYSE American:$OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at The MicroCap Conference on Oct 1, 2018, at 1:00 PM EST.pic.twitter.com/UipSxqqoUT
Prikaži ovu nit -
#Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of#AG013 for Oral#Mucositis$OGEN http://www.1stoncology.com/blog/oragenics-reports-positive-interim-safety-analysis-results-from-its-phase-2-clinical-trial-of-ag013-for-oral-mucositis … -
-
(Business Wire)
#Oragenics Completes Enrollment for the Interim Analysis Cohort in Its.. https://www.storiesflow.com/48641804/ag013-oragenics-completes-enrollment-interim-analysis-cohort-phase-clinical-trial-oral-mucositis …pic.twitter.com/n0CjI6ULUE
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.